NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
Clinical Trials
17 trialsNCT02446600 2026-03-05
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04884360 2026-03-02
MONO-OLA1
AstraZeneca
Phase 3 Active not recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT04421963 2026-01-21
ROSY-O
AstraZeneca
Phase 3 Active not recruiting
NCT06712472 2026-01-20
RAINBO-RED
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT06580314 2026-01-14
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT04269200 2025-12-23
DUO-E
AstraZeneca
Phase 3 Active not recruiting
NCT01844986 2025-12-10
SOLO-1
AstraZeneca
Phase 3 Active not recruiting
NCT03740165 2025-10-22
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01874353 2025-08-03
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
AstraZeneca
Phase 3 Active not recruiting
NCT03737643 2025-01-29
DUO-O
AstraZeneca
Phase 3 Active not recruiting
NCT03402841 2024-08-21
OPINION
AstraZeneca
Phase 3 Completed
NCT03278717 2022-09-27
ICON9
University College, London
Phase 3 Unknown
NCT02477644 2022-08-02
PAOLA-1
Arcagy Research
Phase 3 Completed
NCT02282020 2022-07-26
SOLO3
AstraZeneca
Phase 3 Completed
NCT02392676 2016-05-02
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
AstraZeneca
Phase 3 Withdrawn